UBS has reaffirmed its 'buy' recommendation on Merck KGaA, with its price target raised from €172 to €186, a new target that offers 17% upside potential for the German chemicals and healthcare group's shares.

The broker explains that it is updating its model to take account of the results for the last quarter of 2023, with an increase in the valuations of the life sciences and electronics businesses as part of its SOTP (sum of parts) methodology.

Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.